Welcome to our dedicated page for Trevi Therapeutics news (Ticker: TRVI), a resource for investors and traders seeking the latest updates and insights on Trevi Therapeutics stock.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing Haduvio™ (oral nalbuphine extended-release) as an investigational therapy for chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). The Trevi Therapeutics news feed on this page brings together company announcements, clinical data updates, and financial disclosures that relate directly to TRVI stock and its development programs.
News items commonly include results from key clinical trials such as the Phase 2b CORAL trial in IPF chronic cough and the Phase 2a RIVER trial in RCC, along with information on additional studies like respiratory safety and drug–drug interaction trials. Trevi’s releases also describe regulatory milestones, including End-of-Phase 2 interactions with the U.S. Food and Drug Administration for chronic cough in IPF, and outline planned Phase 3 and Phase 2b programs.
Investors and followers of TRVI can also find corporate and financial updates in the news stream, including quarterly financial results, capital-raising transactions, and participation in healthcare and investor conferences. Management changes and other material events are typically reported through press releases that are also furnished to the U.S. Securities and Exchange Commission on Form 8-K.
By reviewing the Trevi Therapeutics news page, readers can monitor how the company reports progress in its chronic cough indications, how clinical data are presented at scientific meetings, and how management describes its strategy for advancing Haduvio. This centralized news view helps provide context for developments that may influence perceptions of Trevi’s clinical pipeline and regulatory trajectory.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Trevi Therapeutics (NASDAQ: TRVI) announced participation in several investor events in May 2023. The events include the Aegis Virtual Conference from May 2-4, where senior management will present on May 3, and the American Thoracic Society's Respiratory Innovation Summit from May 19-20, with a presentation on May 20. Additionally, Trevi will be featured at the Yale Innovation Summit from May 31 to June 1. The focus of Trevi Therapeutics is on Haduvio™, an investigational therapy for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and other conditions. Haduvio aims to provide a novel treatment through an oral formulation of nalbuphine. Trevi's leadership, including President and CEO Jennifer Good, will address investors at these key events.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) announced participation in the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023, at 11:00 a.m. ET. Key executives, including Jennifer Good (CEO), Lisa Delfini (CFO), and David Clark (CMO), will engage in a fireside chat. They will also hold investor meetings during the conference. Trevi is developing the investigational therapy Haduvio™ (oral nalbuphine ER) for chronic cough related to idiopathic pulmonary fibrosis and prurigo nodularis. A live webcast will be available on the company's website, with an archived replay accessible for 30 days post-event. Haduvio is a mixed receptor agonist and antagonist, targeting cough mediation. Safety and efficacy evaluations are pending regulatory review.
Trevi Therapeutics (TRVI) announced its fourth quarter and full-year 2022 financial results, reporting a net loss of $5.5 million for Q4, down from $8.5 million in Q4 2021. Total operating expenses decreased to $6.7 million, driven by lower R&D costs of $4.3 million. As of December 31, 2022, Trevi had $120.5 million in cash and marketable securities, which supports operations into 2026. The company plans multiple trial initiations for its investigational therapy Haduvio in chronic cough and prurigo nodularis in 2023, with FDA discussions ongoing. The full data from the Phase 2b/3 PRISM trial is expected in Q2 2023.
Trevi Therapeutics (Nasdaq: TRVI) announced a conference call scheduled for March 16, 2023, at 4:30 p.m. ET to discuss its fourth quarter and full-year financial results for 2022. The company, focused on developing Haduvio™ (oral nalbuphine ER) for chronic cough associated with idiopathic pulmonary fibrosis (IPF) and prurigo nodularis, encourages participation via phone or webcast. Haduvio is a mixed μ-opioid receptor antagonist and κ-opioid receptor agonist, with safety and efficacy not yet evaluated by regulatory authorities. More information can be accessed from their official website.